Free Trial

Dawson James' Rating of Bluejay Diagnostics on 8/3/2023

On August 3, 2023, Dawson James updated its outlook on Bluejay Diagnostics (NASDAQ:BJDX) with the action "Downgrade", setting a "Neutral" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Dawson James

DateCompanyAction
2/28/2024
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Initiated Coverage
1/30/2024
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Downgrade
9/27/2023
Byrna Technologies Inc. stock logo
BYRN
Byrna Technologies
Downgrade
8/15/2023
22nd Century Group, Inc stock logo
XXII
22nd Century Group
Lower Price Target
7/25/2023
22nd Century Group, Inc stock logo
XXII
22nd Century Group
Lower Price Target
7/17/2023
Tharimmune, Inc. stock logo
THAR
Tharimmune
Downgrade
More Ratings From Dawson James